Global Point-of-Care or Rapid Testing Kit Market Size By Type (Blood Glucose Testing, Infectious Diseases Testing), By Application (Clinics, Hospitals), By Region, And Segment Forecasts, 2023 to 2032

The Global Point-of-Care or Rapid Testing Kit Market was valued at USD 36.2 billion in 2023 and is projected to surpass USD 64.9 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2023–2031). The market is expanding due to increased demand for real-time diagnostic solutions, rising incidences of infectious and chronic diseases, and the global emphasis on decentralized healthcare models. The integration of advanced technologies such as AI-driven diagnostics, digital health connectivity, and miniaturized testing systems is transforming the point-of-care (POC) ecosystem across hospitals, clinics, pharmacies, and even homecare settings.

Drivers:

1. Growing Burden of Chronic and Infectious Diseases

Chronic conditions like diabetes, cardiovascular disorders, and respiratory infections are on the rise globally. This trend drives the adoption of rapid diagnostic kits that offer immediate clinical insights, enabling early intervention and improved disease management.

2. Technological Advancements in Testing Kits

Advancements in biosensor technologies, lab-on-a-chip systems, and smartphone-based diagnostics are enhancing the accuracy, usability, and portability of point-of-care testing kits. These innovations cater to both high- and low-resource settings.

3. Decentralization of Healthcare Delivery

The shift from centralized diagnostics to more accessible, patient-centric care models is fueling demand for POC solutions. Home-based testing, supported by telemedicine and connected devices, is becoming increasingly popular.

Restraints:

1. Regulatory and Reimbursement Challenges

The market is hindered by stringent regulatory pathways for approval and inconsistent reimbursement frameworks across different regions. This can delay product launches and affect market penetration.

2. Accuracy Concerns in Low-Complexity Settings

Although POC kits are designed for convenience, ensuring high sensitivity and specificity outside laboratory environments remains a challenge. Variability in sample handling and user training can impact test reliability.

Opportunity:

1. Expansion in Emerging Markets

Emerging economies are investing in improving their healthcare infrastructure and access to diagnostics. POC testing kits provide scalable, cost-effective solutions for rural and underserved regions.

2. Pandemic Preparedness and Surveillance Programs

Governments and global health agencies are increasing investments in pandemic preparedness and real-time surveillance systems. Rapid testing kits are vital components of these strategies, presenting vast growth opportunities for manufacturers.

Market by System Type Insights:

Based on system type, the Lateral Flow Assay (LFA) segment held the largest share in 2023. LFAs are widely used due to their ease of use, cost-efficiency, and rapid results, particularly for infectious disease detection such as COVID-19, HIV, and malaria. Meanwhile, Molecular Diagnostic Kits are projected to grow at the fastest rate, driven by rising demand for high-sensitivity tests for respiratory and sexually transmitted infections.

Market by End-Use Insights:

The Hospitals and Clinics segment dominated the end-use market in 2023, accounting for the highest revenue. Hospitals prefer POC kits for emergency and outpatient departments, where time-sensitive diagnostics are critical. The Home Care segment is also witnessing rapid growth, fueled by consumer-friendly test kits, eHealth integration, and patient empowerment trends.

Market by Regional Insights:

North America led the global market in 2023, thanks to robust healthcare infrastructure, high adoption of advanced diagnostics, and the presence of key manufacturers. Asia-Pacific, however, is expected to register the highest growth during the forecast period. Rapid urbanization, rising healthcare expenditure, and the expansion of digital health initiatives in countries like China, India, and Southeast Asia are major contributors to regional growth.

Competitive Scenario:

Leading players in the Global Point-of-Care or Rapid Testing Kit Market include Abbott Laboratories, Roche Diagnostics, Becton Dickinson & Company, Siemens Healthineers, QuidelOrtho Corporation, Thermo Fisher Scientific, BioMérieux SA, Danaher Corporation, Nova Biomedical, and Chembio Diagnostics. These companies are focusing on expanding their POC portfolios through partnerships, acquisitions, and technological innovations.

Key Market Developments:

In 2023, Abbott Laboratories launched a next-gen rapid COVID-19 and influenza combo test for home use.

In 2024, Roche Diagnostics introduced a cloud-integrated POC platform for real-time result sharing with healthcare providers.

In 2025, QuidelOrtho Corporation expanded its product line by acquiring a startup specializing in rapid molecular diagnostics for sexually transmitted diseases.

Scope of Work – Global Point-of-Care or Rapid Testing Kit Market

Report Metric Details

Market Size (2023) USD 36.2 billion

Projected Market Size (2031) USD 64.9 billion

CAGR (2023–2031) 7.4%

Market Segments By System Type (LFA, Molecular Diagnostics, Others); By End-use (Hospitals, Clinics, Home Care, Diagnostic Centers)

Growth Drivers Rise in chronic and infectious diseases, technology integration, demand for decentralized healthcare

Opportunities Emerging markets, government investments in disease surveillance, home diagnostics adoption

FAQs: